News and Press Releases

Sound Bioventures expands portfolio with new investment in US company NephroDI Therapeutics to accelerate development of NDI-5001 for pediatric orphan kidney disease

New funding will accelerate NephroDI’s asset, NDI-5001, into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI) New investment complements NephroDI’s previously announced strategic corporate partnership NDI-5001...

Category: Clinical Trials, Drug Delivery, Drug Discovery, Other
Posted: June 20, 2024

Epic Spaces, Nordenskiöldsgatan 11A, 211 19 Malmö, Sweden